REGN-EB3: First Approval.

Abstract

REGN-EB3 (INMAZEB®, Regeneron Pharmaceuticals) is a combination of three fully-human monoclonal antibodies-atoltivimab (REGN3470), maftivimab (REGN3479), and odesivimab (REGN3471) -that target Ebola virus glycoprotein. Based on the results of the PALM study conducted during an Ebola outbreak in the Democratic Republic of Congo, REGN-EB3 was recently approved by the US FDA as a treatment for Ebola virus infection. This article summarizes the milestones in the development of REGN-EB3 leading to this first approval for the treatment of infection caused by Zaire ebolavirus (Ebola virus) in adult and paediatric patients.

• Authors: Anthony Markham
• Journal: Drugs (Drugs) Vol. 81 Issue 1 Pg. 175-178 (Jan 2021) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 33432551 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• Antiviral Agents
• Drug Combinations
• atoltivimab, maftivimab, and odesivimab-ebgn drug combination

Topics

• Antibodies, Monoclonal, Humanized (chemistry, pharmacology)
• Antiviral Agents (chemistry, pharmacology)
• Drug Combinations
• Ebolavirus (drug effects)
• Hemorrhagic Fever, Ebola (drug therapy)
• Humans